By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Biotechnology
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Institution %: 98.579
YTD Institution change: 3198907
InsidersInsiders %: 4.665
Insiders Purchases YTD:
Insiders Sales YTD: 112569
Insiders Net YTD: -112569
Analyst RatingsTarget Price: 90.56
Overall Rating: 4.5263
Strong Buys (5): 12
Buys (4): 5
Holds (3): 2
Sells (2): 0
Strong Sells (1): 0
52 Week Hi: 54.98
52 Week Low: 31.52
Beta: 0.719
50 Day MA: 36.0444
200 Day MA: 41.2939
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.081
Forward PE:
Trailing PE: